A5047540200- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Neutropenia and Cancer Infections
- Viral-associated cancers and disorders
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Blood disorders and treatments
- Fibroblast Growth Factor Research
- Bladder and Urothelial Cancer Treatments
- Sarcoma Diagnosis and Treatment
- Synthesis and Biological Evaluation
- Chemokine receptors and signaling
- PI3K/AKT/mTOR signaling in cancer
- Biosimilars and Bioanalytical Methods
- Hematological disorders and diagnostics
- Homelessness and Social Issues
- Cancer Mechanisms and Therapy
- Biological Research and Disease Studies
- vaccines and immunoinformatics approaches
Janssen (United States)
2018-2024
Johnson & Johnson (United States)
2024
University of California, San Francisco
2023
Dana-Farber Cancer Institute
2023
Harvard University
2023
Commonly used first-line (1L) treatments for mantle cell lymphoma include high-dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) younger patients and several chemoimmunotherapy regimens older patients. Continuous debates exist on the role of ASCT in maintenance rituximab (MR) after bendamustine plus (BR).Retrospective data from 4,216 with Flatiron Health electronic record-derived deidentified database diagnosed between 2011 2021, mostly US community oncology...
In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes minimal residual disease (MRD) kinetics and any potential predictive value for PFS, as it has not yet been evaluated treatment.
Abstract Background Patients with relapsed/refractory multiple myeloma are at increased risk of infection. Infections during treatment teclistamab, the first B‐cell maturation antigen‐directed bispecific antibody approved for triple‐class–exposed myeloma, was examined in phase 1/2 MajesTEC‐1 study. Methods ( N = 165) received subcutaneous teclistamab 1.5 mg/kg weekly after a step‐up dosing schedule (0.06 and 0.3 mg/kg, each separated by 2–4 days). were monitored frequently infections;...
Summary This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D‐VCd) in newly diagnosed multiple myeloma (NDMM) relapsed (RMM). Patients received 4–8 induction cycles bortezomib 1·5 mg/m 2 , 300 40 mg weekly. Intravenous daratumumab 16 mg/kg was administered as approved except for a split‐first dose Cycle 1. Eligible patients underwent autologous stem cell transplantation. All ≤12 maintenance doses monthly. Eighty‐six...
The long-term outcome for patients with mantle cell lymphoma (MCL) has been improving; however, historical evidence indicates that progression-free survival (PFS) declines and high-risk factors accumulate each successive line of chemoimmunotherapy (CIT).1,2 Median PFS CIT declined by 70% from first-line (1L) (47.4 mo) to second-line (14.0 86% after third-line therapy (6.5 mo),1 emphasizing a need therapies will reverse or mitigate these trends. Ibrutinib is once-daily, oral inhibitor...
8034 Background: Teclistamab is the first B-cell maturation antigen (BCMA) bispecific antibody approved for treatment of relapsed/refractory multiple myeloma (RRMM) at a dose 1.5 mg/kg weekly (QW) given subcutaneously. A less frequent dosing schedule offers added convenience and flexibility to patients, physicians, caregivers. We evaluated ability patients maintain their responses after transitioning from QW every other week (Q2W) schedules in pivotal phase 1/2 MajesTEC-1 trial...
7517 Background: Emerging data suggest that administering toci prior to bispecific antibodies reduces the incidence of CRS, which may support outpatient therapy initiation. We previously showed CRS with teclistamab, first approved BCMA×CD3 antibody weight-based dosing for treatment pts triple-class exposed RRMM, was reduced from 72% in overall MajesTEC-1 study population 26% a cohort receiving single dose before teclistamab step-up dose. Here, we present an updated analysis longer-term...
Background. Previous studies of maltreatment children born to women who used cocaine during pregnancy have relied on either selected samples infants identified at birth or biased, high-risk referred protective services. Objective. To determine the relative risk placement outside home first 2 years life in compared with a sociodemographically similar comparison group. Patients. We reviewed medical records consecutive deliveries Yale-New Haven Hospital from August 1, 1989 through September 30,...
Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines prior platinum-based chemotherapy.To better understand frequency management select treatment-emergent adverse events (TEAEs) to enable optimal fibroblast growth factor receptor inhibitor (FGFRi) treatment.Longer-term efficacy safety results BLC2001 (NCT02365597) trial in patients advanced unresectable metastatic...
Abstract Introduction Ciltacabtagene autoleucel (cilta‐cel) is a novel chimeric antigen receptor T‐cell therapy that being evaluated in the CARTITUDE‐1 trial (NCT03548207) patients with relapsed or refractory multiple myeloma (RRMM) who received as part of their previous an immunomodulatory drug, proteasome inhibitor, and anti‐CD38 monoclonal antibody (i.e., triple‐class exposed). Given absence control arm CARTITUDE‐1, this study assessed comparative effectiveness cilta‐cel physician's...
In the primary analysis of LYRA, daratumumab + cyclophosphamide/bortezomib/dexamethasone (DARA CyBorD) was effective and well tolerated in newly diagnosed multiple myeloma (NDMM) relapsed (RMM). We report final LYRA (median months follow-up: NDMM, 35.7; RMM, 35.3) after all patients completed study therapy, were followed for 36 months, or discontinued. Patients received DARA CyBorD induction, autologous stem cell transplant (if eligible), 12 maintenance. Eighty-seven NDMM enrolled, 39...
Ciltacabtagene autoleucel (cilta-cel) is a novel agent being investigated in the single-arm CARTITUDE-1 trial (NCT03548207) for patients with relapsed or refractory multiple myeloma who are triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and anti-CD38 monoclonal antibody. The objective of this study was evaluate comparative efficacy cilta-cel vs physician's choice treatment, as no head-to-head trials have been conducted. An external control arm created from long-term...
Aim: We compared the effectiveness of teclistamab versus real-world physician's choice therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC-1 eligibility criteria were applied to RWPC cohort. Baseline covariate imbalances adjusted using inverse probability treatment weighting. Overall survival, progression-free survival and time next compared. Results: After weighting, baseline characteristics similar between cohorts (teclistamab, n =...
7504 Background: MCL is a non-Hodgkin lymphoma with heterogeneous biology and outcomes. We characterized RW tx patterns outcomes of pts to identify factors associated in the US. Methods: This retrospective study included adult diagnosed Jan 2011-Nov 2020 nationwide Flatiron Health EHR-derived deidentified database. Pt characteristics, patterns, time next (rwTTNT, defined as start first-line [1L] subsequent or death) rwOS were evaluated. Results: 3455 included, 85.3% from community oncology...
8045 Background: Pts with RRMM who are triple-class exposed (to immunomodulatory drugs [IMiDs], proteasome inhibitors [PIs] and an anti-CD38 antibody) cycle through multiple salvage regimens progressively worse outcomes. CARTITUDE-1 (NCT03548207) is a single-arm phase 1b/2 study evaluating cilta-cel, chimeric antigen receptor T-cell therapy 2 B-cell maturation antigen–targeting single-domain antibodies, in pts received ≥3 prior lines of (LOT) or were double refractory to IMiD PI, exposed,...
ObjectivesUnequivocal clinical progression (UCP)—a worsening of status with or without radiographic (RAD)—represents a distinct mode disease in metastatic prostate cancer. We evaluated the prevalence, risk factors and impact UCP on survival outcomes.MethodsA post-hoc analysis COU-AA-302, randomised phase 3 study abiraterone plus prednisone (AAP) versus was performed. Baseline characteristics were summarised. Cox proportional-hazards model Kaplan-Meier method used for time to event analyses,...